Eric Dusseux, MD, MSc, MBAChief Executive Officer
Prior to joining Bionik, Dr. Dusseux was President of Europe and a director for Auregen BioTherapeutics SA, a 3D bioprinting tissue engineering biotechnology company headquartered in Switzerland, that he formed while at Bemido SA, a family office, with the support of Gurnet Point Capital and Waypoint.
From 2012 through 2016, Dr. Dusseux served as an Executive Committee Member in the Corporate Strategy Department of Sanofi Pasteur, the vaccine division of Sanofi. Among other responsibilities, Dr. Dusseux, Vice-President Corporate Strategy, was responsible for business intelligence, strategic and business planning, and corporate development.
Before joining Sanofi Pasteur, Dr. Dusseux served as Vice-President, MAGE-A3 Medicines Development Leader, within the Immunotherapeutics Business Unit at GSK Biologicals, a division of GlaxoSmithKline, in charge of therapeutic vaccines against cancer.
Dr. Dusseux also gained significant experience providing strategic advice for numerous pharmaceutical, medical device, payer and biotechnology clients, while working for the Boston Consulting Group from 2002 to 2007.
Dr. Dusseux is a Medical Doctor, specializing in Public Health. Dr. Dusseux also holds a Master of Science in Physical Chemistry and is a graduate of the French Business School H.E.C. in Paris (MBA, Isa).
Michal PrywataCo-Founder and Chief Technology Officer
Mr. Prywata is the co-founder and Chief Technology Officer of Bionik Laboratories. He studied biomedical engineering at Ryerson University and has a proven track record of inventing and winning technology showcases. While attending Ryerson, Mr. Prywata co-invented the world’s first robotic, prosthetic arm that is controlled by brain signals. Equally impressive is his strong understanding of developing technologies that address significant and untapped markets. He is responsible for raising the initial capital to found Bionik and turn numerous concepts into products.
Loren WassChief Commercial Officer
Wass joined BIONIK from ReWalk Robotic, where as Vice President of Sales and Reimbursement he was responsible for the commercialization of several rehabilitation robotic exoskeletons, including the first robotic exoskeleton cleared by the FDA for paralyzed individuals to use to ambulate at home and in the community and the first soft exo-suit cleared by the FDA for stroke gait therapy in a clinical setting. In the first full year after FDA clearance, Wass grew sales by 60% year-over-year. He also led all efforts in reimbursement leading to a national coverage policy by the U.S. Veterans Association and numerous positive coverage decisions by private health insurers. Mr. Wass served on ReWalk’s Executive Committee that was responsible for the overall management and strategic direction of the company.
Prior to ReWalk, Mr. Wass held several key sales leadership roles. He served as Vice President of Sales for DJO (DonJoy Orthopedics), where he led a team of more than 250 direct and distributor-based sales representatives and exceeded new product launch goals by 15%. Additionally, he held a leadership role in several merger activities while there. Before joining DJO, Mr. Wass served as National Sales Director at Ottobock, and held the position of Vice President of Sales and Field Operations for Myomo, Inc. He brings more than 25 years of experience in the orthopedic and neurological rehabilitation market to his role at BIONIK.
Richard Russo, Jr., CPAChief Financial Officer
Richard Russo, Jr. has served as the Company’s Chief Financial Officer since November 2020. He has over 15 years of finance and accounting leadership experience and holds a CPA.
From 2017-2020, Russo, Jr. served as Vice President of Finance and U.S. Chief Financial Officer of ICarbonX, where he was responsible for the merger of 3 companies, fundraising, and the ultimate dissolution of the U.S. companies.
From 2007-2016, Russo, Jr. held various key leadership roles for NASDAQ listed companies in life sciences, pharmaceutical and medical device industries. He served as Corporate Controller for Pieris Pharmaceuticals, Inc., a clinical stage biotechnology company, Juniper Pharmaceuticals, a woman’s health company focused on developing therapeutics and Cynosure, a medical device company focused on aesthetic treatment systems. In each of these roles, Russo, Jr. was responsible for all finance activities and SEC reporting along including partnering closely with the business leaders to ensure effective and efficient financial procedures throughout the organization.
Russo, Jr. started his career in 2005, where he served as an auditor at Pricewaterhouse Coopers in the assurance group.